Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Dose escalation of the anti-CD47 TTI-622 in NHL

Krish Patel • 13 Dec 2021
ASH 2021
Lymphoma Non-Hodgkin Lymphoma TTI-622

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, provides an overview of data from the ongoing, multicenter Phase Ia/Ib dose-escalation and expansion trial (NCT03530683) of TTI-622, an anti-CD47 therapy, in patients with advanced relapsed/refractory non-Hodgkin lymphoma (NHL). Preliminary safety and pharmacokinetic data suggests encouraging activity and low rates of toxicity in patients, and further research in the trial will elucidate the optimal dosing regimen. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Krish Patel

1:01
The current landscape of antibody-based therapies in R/R DLBCL
Krish Patel • 11 Dec 2023
1:31
Clinical outcomes are poor for CLL patients treated with venetoclax post-BTKi exposure
Krish Patel • 11 Dec 2023
1:25
Hypertension prevalence in CLL and how it is affected by acalabrutinib treatment
Krish Patel • 11 Dec 2023
1:06
Pirtobrutinib in R/R MZL: insights from the BRUIN trial
Krish Patel • 11 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals